Market Cap 1.35B
Revenue (ttm) 7.02M
Net Income (ttm) -157.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,248.72%
Debt to Equity Ratio 0.00
Volume 898,700
Avg Vol 942,554
Day's Range N/A - N/A
Shares Out 66.38M
Stochastic %K 46%
Beta 1.33
Analysts Strong Sell
Price Target $59.62

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibit...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 200 7500
Fax: 908 454 1911
Address:
Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States
lucabrix
lucabrix Jun. 24 at 7:28 PM
$CLDX 200MA at 25 is thereal game changer
0 · Reply
Steve1545
Steve1545 Jun. 24 at 4:57 PM
$CLDX breaking out? 🫢
0 · Reply
Wolfofwannabe
Wolfofwannabe Jun. 23 at 3:07 PM
0 · Reply
FactsPlease99
FactsPlease99 Jun. 16 at 5:42 PM
$CLDX Freaking hilarious. “ on Stocktwits retail investors stay bearish” They must be talking about me 🤣
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 3:36 PM
HC Wainwright & Co. updates rating for Celldex Therapeutics ( $CLDX ) to Buy, target set at 50.
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 16 at 2:18 AM
Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded $CLDX https://stocktwits.com/news/equity/markets/celldex-study-finds-most-patients-symptom-free-from-angioedema-after-one-year-retail-bulls-stay-guarded/chln9MlRRbr
0 · Reply
DonCorleone77
DonCorleone77 Jun. 16 at 12:46 AM
$CLDX Celldex announces data on barzolvolimab from its Phase 2 trial in CSU Celldex Therapeutics announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria, CSU. The data were presented today by Dr. Martin Metz in an oral presentation at the European Academy of Allergy and Clinical Immunology, EAACI, Congress 2025. Celldex previously announced that the Phase 2 study in CSU met its primary and secondary endpoints at 12 weeks with clinically meaningful and statistically significant decreases in UAS7 compared to placebo across multiple dose groups, including improvements in quality of life and angioedema measurements, and demonstrated a favorable safety profile. The data presented further support these results by demonstrating improvements in AAS7 and additional measures of angioedema control over the 52 week treatment period. AAS7 measures the frequency and intensity of angioedema episodes, where higher scores indicate increased angioedema activity.
0 · Reply
AlertsAndNews
AlertsAndNews Jun. 14 at 7:05 PM
$CLDX Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 Celldex reported that 77% of patients (150 mg Q4W) with baseline angioedema were angioedema free at Week 52 in its Phase 2 trial for chronic spontaneous urticaria (CSU). The new data further support barzolvolimab’s clinical benefit and build on previous results showing meaningful improvements in angioedema control, urticaria scores, and quality of life over a year of treatment.
0 · Reply
FactsPlease99
FactsPlease99 Jun. 13 at 4:23 PM
$CLDX wow may close red 😂
1 · Reply
FactsPlease99
FactsPlease99 Jun. 13 at 3:34 PM
$CLDX Not surprised…. like always selling off.
0 · Reply
Latest News on CLDX
Celldex Therapeutics: Rising High, With Room For Further Growth

May 10, 2024, 10:44 AM EDT - 1 year ago

Celldex Therapeutics: Rising High, With Room For Further Growth


MoneyShow's Best Investment Ideas For 2024: Part 2

Jan 26, 2024, 5:30 PM EST - 1 year ago

MoneyShow's Best Investment Ideas For 2024: Part 2

ANET BAX BIP BLK BP CCJ CSTE


lucabrix
lucabrix Jun. 24 at 7:28 PM
$CLDX 200MA at 25 is thereal game changer
0 · Reply
Steve1545
Steve1545 Jun. 24 at 4:57 PM
$CLDX breaking out? 🫢
0 · Reply
Wolfofwannabe
Wolfofwannabe Jun. 23 at 3:07 PM
0 · Reply
FactsPlease99
FactsPlease99 Jun. 16 at 5:42 PM
$CLDX Freaking hilarious. “ on Stocktwits retail investors stay bearish” They must be talking about me 🤣
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 3:36 PM
HC Wainwright & Co. updates rating for Celldex Therapeutics ( $CLDX ) to Buy, target set at 50.
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 16 at 2:18 AM
Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded $CLDX https://stocktwits.com/news/equity/markets/celldex-study-finds-most-patients-symptom-free-from-angioedema-after-one-year-retail-bulls-stay-guarded/chln9MlRRbr
0 · Reply
DonCorleone77
DonCorleone77 Jun. 16 at 12:46 AM
$CLDX Celldex announces data on barzolvolimab from its Phase 2 trial in CSU Celldex Therapeutics announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria, CSU. The data were presented today by Dr. Martin Metz in an oral presentation at the European Academy of Allergy and Clinical Immunology, EAACI, Congress 2025. Celldex previously announced that the Phase 2 study in CSU met its primary and secondary endpoints at 12 weeks with clinically meaningful and statistically significant decreases in UAS7 compared to placebo across multiple dose groups, including improvements in quality of life and angioedema measurements, and demonstrated a favorable safety profile. The data presented further support these results by demonstrating improvements in AAS7 and additional measures of angioedema control over the 52 week treatment period. AAS7 measures the frequency and intensity of angioedema episodes, where higher scores indicate increased angioedema activity.
0 · Reply
AlertsAndNews
AlertsAndNews Jun. 14 at 7:05 PM
$CLDX Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 Celldex reported that 77% of patients (150 mg Q4W) with baseline angioedema were angioedema free at Week 52 in its Phase 2 trial for chronic spontaneous urticaria (CSU). The new data further support barzolvolimab’s clinical benefit and build on previous results showing meaningful improvements in angioedema control, urticaria scores, and quality of life over a year of treatment.
0 · Reply
FactsPlease99
FactsPlease99 Jun. 13 at 4:23 PM
$CLDX wow may close red 😂
1 · Reply
FactsPlease99
FactsPlease99 Jun. 13 at 3:34 PM
$CLDX Not surprised…. like always selling off.
0 · Reply
NJgolfer
NJgolfer Jun. 13 at 2:39 PM
$CLDX breakout today on higher than average volume from multi month base.
0 · Reply
topstockalerts
topstockalerts Jun. 13 at 2:05 PM
$CLDX showing high relative strength.. Stay tuned for more!💰💰💰
0 · Reply
Boketaw
Boketaw Jun. 13 at 1:49 PM
$CLDX initiated a position last evening. I am long!!!
0 · Reply
Steve1545
Steve1545 Jun. 13 at 1:40 PM
1 · Reply
topstockalerts
topstockalerts Jun. 13 at 12:17 PM
$CLDX where's she going once market opens? ...🚨🚨...
0 · Reply
FactsPlease99
FactsPlease99 Jun. 13 at 12:14 PM
$CLDX there target was $80? so did they reduce it
0 · Reply
JarvisFlow
JarvisFlow Jun. 13 at 12:00 PM
HC Wainwright & Co. has updated their rating for Celldex Therapeutics ( $CLDX ) to Buy with a price target of 50.
0 · Reply
briefingcom
briefingcom Jun. 13 at 11:53 AM
Gapping Up: $RH +20.1% $NEXT +9% $USO +6.5% $CLDX +5.7% $NOG +4.7%
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 13 at 11:53 AM
$CLDX (+5.6% pre) Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 - SI https://ooc.bz/l/67949
0 · Reply
BioTechChap
BioTechChap Jun. 13 at 9:34 AM
$CLDX $JSPR $BPMC https://ir.celldex.com/news-releases/news-release-details/celldex-presents-unprecedented-76-week-results-barzolvolimab
0 · Reply
knowthyself
knowthyself Jun. 12 at 10:09 PM
$CLDX excellent data
0 · Reply
knowthyself
knowthyself Jun. 12 at 9:40 PM
0 · Reply